JP2007505923A5 - - Google Patents

Download PDF

Info

Publication number
JP2007505923A5
JP2007505923A5 JP2006527060A JP2006527060A JP2007505923A5 JP 2007505923 A5 JP2007505923 A5 JP 2007505923A5 JP 2006527060 A JP2006527060 A JP 2006527060A JP 2006527060 A JP2006527060 A JP 2006527060A JP 2007505923 A5 JP2007505923 A5 JP 2007505923A5
Authority
JP
Japan
Prior art keywords
gene
immunogenic composition
hiv
dna
dna immunogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006527060A
Other languages
English (en)
Japanese (ja)
Other versions
JP4989224B2 (ja
JP2007505923A (ja
Filing date
Publication date
Priority claimed from US10/941,164 external-priority patent/US7488485B2/en
Application filed filed Critical
Publication of JP2007505923A publication Critical patent/JP2007505923A/ja
Publication of JP2007505923A5 publication Critical patent/JP2007505923A5/ja
Application granted granted Critical
Publication of JP4989224B2 publication Critical patent/JP4989224B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006527060A 2003-09-16 2004-09-16 Dnaワクチン組成物およびその使用方法 Expired - Fee Related JP4989224B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US50319703P 2003-09-16 2003-09-16
US60/503,197 2003-09-16
US10/941,164 2004-09-15
US10/941,164 US7488485B2 (en) 2003-09-16 2004-09-15 DNA vaccine compositions and methods of use
PCT/US2004/030512 WO2005027844A2 (en) 2003-09-16 2004-09-16 Dna vaccine compositions and methods of use

Publications (3)

Publication Number Publication Date
JP2007505923A JP2007505923A (ja) 2007-03-15
JP2007505923A5 true JP2007505923A5 (cg-RX-API-DMAC7.html) 2011-01-20
JP4989224B2 JP4989224B2 (ja) 2012-08-01

Family

ID=34381064

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006527060A Expired - Fee Related JP4989224B2 (ja) 2003-09-16 2004-09-16 Dnaワクチン組成物およびその使用方法

Country Status (13)

Country Link
US (3) US7488485B2 (cg-RX-API-DMAC7.html)
EP (1) EP1667523B1 (cg-RX-API-DMAC7.html)
JP (1) JP4989224B2 (cg-RX-API-DMAC7.html)
AU (1) AU2004273965B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0414442A (cg-RX-API-DMAC7.html)
CA (1) CA2538840C (cg-RX-API-DMAC7.html)
DK (1) DK1667523T3 (cg-RX-API-DMAC7.html)
ES (1) ES2399875T3 (cg-RX-API-DMAC7.html)
IL (1) IL174325A (cg-RX-API-DMAC7.html)
NZ (1) NZ545954A (cg-RX-API-DMAC7.html)
PL (1) PL1667523T3 (cg-RX-API-DMAC7.html)
PT (1) PT1667523E (cg-RX-API-DMAC7.html)
WO (1) WO2005027844A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488485B2 (en) * 2003-09-16 2009-02-10 University Of Kansas Medical Center DNA vaccine compositions and methods of use
US8765140B2 (en) * 2003-09-16 2014-07-01 University Of Kansas Medical Center DNA vaccine compositions with HIV/SIV gene modifications
ES2541771T3 (es) * 2005-05-03 2015-07-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Expresión de una proteína mitocondrial mediante un enfoque alotópico mejorado
US7585675B2 (en) * 2005-11-15 2009-09-08 University Of Kansas Medical Center Inhibition of HIV and SHIV replication with antisense interleukin-4
FR2979919B1 (fr) * 2011-09-12 2015-12-11 Centre Nat Rech Scient Genomes lentiviraux chimeriques non-integratifs comme vaccins innovants contre vih-1
US20130337009A1 (en) * 2012-02-21 2013-12-19 Immunogenetix Therapeutics, Inc. Chimeric dna vaccine compositions and methods of use
AU2020315598B2 (en) 2019-07-16 2024-12-12 Gilead Sciences, Inc. HIV vaccines and methods of making and using
CA3202466A1 (en) 2021-01-14 2022-07-21 Jiani LI Hiv vaccines and methods of using
AU2022208435A1 (en) 2021-01-18 2023-08-10 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6531123B1 (en) * 1997-05-01 2003-03-11 Lung-Ji Chang Lentiviral vectors
US7488485B2 (en) * 2003-09-16 2009-02-10 University Of Kansas Medical Center DNA vaccine compositions and methods of use
US7122180B2 (en) * 2000-10-23 2006-10-17 Children's Medical Center Corporation DNA vectors containing mutated HIV proviruses

Similar Documents

Publication Publication Date Title
Cohen et al. Human immunodeficiency virus vpr product is a virion-associated regulatory protein
Gurgo et al. Envelope sequences of two new United States HIV-1 isolates
DK0495811T3 (da) Produktion af gensplejsede vacciner mod AIDS og andre retrovirussygdomme
JP2010535495A5 (cg-RX-API-DMAC7.html)
Johnson et al. Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge.
Abimiku et al. Subgroup G HIV type 1 isolates from Nigeria
JP2006523224A5 (cg-RX-API-DMAC7.html)
Yokoyama et al. Molecular evolution of the human immunodeficiency and related viruses.
De Goede et al. Understanding HIV infection for the design of a therapeutic vaccine. Part I: Epidemiology and pathogenesis of HIV infection
ES2683820T3 (es) Uso de proteínas GAG no de subtipo B para encapsidación lentiviral
JP2004509601A5 (cg-RX-API-DMAC7.html)
Salemi et al. The origin and evolution of human T-cell lymphotropic virus type II (HTLV-II) and the relationship with its replication strategy
Franchini et al. Genetic analysis of a new subgroup of human and simian T-lymphotropic retroviruses: HTLV-IV, LAV-2, SBL-6669, and STLV-IIIAGM
EP2128256A3 (en) Molecular clones with mutated HIV GAG/POL, SIV GAG and SIV ENV genes
US5876724A (en) Induction of neutralizing antibody against viral infection by synergy between virus envelope glycoprotein and peptides corresponding to neutralization epitopes of the glycoprotein
JP2007505923A (ja) Dnaワクチン組成物およびその使用方法
JP2008500963A5 (cg-RX-API-DMAC7.html)
Barnett et al. Molecular cloning of the human immunodeficiency virus subtype 2 strain HIV-2UC2
Spire et al. The env gene variability is not directly related to the high cytopathogenicity of an HIV1 variant
Tramont et al. Progress in the development of an HIV vaccine
Yokoyama et al. Molecular phylogeny of the human immunodeficiency and related retroviruses
WO2000018433A3 (en) Use of antigenic complexes of hiv envelope and hla class i antigens as hiv vaccine
Sakai et al. Compatibility of Tat and Rev transactivators in the primate lentiviruses
JP2022536935A5 (cg-RX-API-DMAC7.html)
Hayami et al. Gene-mutated HIV-1/SIV chimeric viruses as AIDS live attenuated vaccines for potential human use